Medulloblastoma Clinical Trials 2024

What are the top hospitals conducting medulloblastoma research?

In the battle against medulloblastoma, a malignant brain tumor commonly found in children, several leading hospitals are driving groundbreaking clinical trials. Children's Hospital Los Angeles takes the lead with an impressive 25 ongoing trials dedicated to medulloblastoma and has conducted a total of 37 trials since their first recorded trial in 1996. This renowned institution in Los Angeles is at the forefront of research for this challenging condition. Meanwhile, Children's Hospital Colorado in Aurora also plays a vital role with 22 active clinical trials and a history of 28 completed studies since their inaugural medulloblastoma trial in 2004.

On the East Coast, Children's National Medical Center in Washington stands out as another significant contributor to medulloblastoma research. With 22 ongoing trials and an impressive track record of completing 37 trials overall since initiating their first one in 1996, they continue to push boundaries and offer hope to patients and families affected by this condition.

Cincinnati Children's Hospital Medical Center is yet another institution making strides against medulloblastoma. They currently have 21 active clinical trials focused on this brain tumor type and have conducted an extensive number of previous investigations totaling up to an astounding count of thirty-seven ever since recording their first medulloblastoma trial back in2004.

Lastly but certainly not least, Cardinal Glennon Children's Medical Center located in Saint Louis brings valuable contributions to the field as well, participating actively with nineteen current medical examinations focusing on combating Medullablatomas while previously conducting twenty-five distinct procedures from its official involvement that initiated during two decades ago precisely around2004.

These esteemed institutions across different locations demonstrate relentless dedication towards unraveling new treatments for medulloblastoma—a complex disease affecting young lives. The collective efforts made by these top hospitals underscore our unwavering commitment toward finding better solutions for those afflicted by this devastating condition—offering rays of hope in the face of adversity.

Which are the best cities for medulloblastoma clinical trials?

In the realm of medulloblastoma clinical trials, several cities emerge as prominent destinations for cutting-edge research. New york City takes the lead with 60 active trials, focusing on studies such as Pharmacological Study, Palbociclib, and Ivosidenib. Following closely behind are Saint Louis in Missouri and Orlando in Florida, both boasting impressive numbers with 56 and 55 ongoing trials respectively. These cities prioritize investigations like Radiation Therapy, Palbociclib, and various pharmacological studies. Other notable locations include Los Angeles in California with 46 active trials and Chicago in Illinois with 43 active trials—both exploring treatment modalities including radiation therapy and pharmacological interventions.

Which are the top treatments for medulloblastoma being explored in clinical trials?

The ongoing clinical trials for medulloblastoma are exploring several promising treatments. Among the top contenders are:

• Cyclophosphamide, a drug currently being tested in two active trials and has been a part of 16 all-time medulloblastoma trials since its introduction in 2001.
• Palbociclib, another treatment showing potential with two active trials and three all-time medulloblastoma studies since it was first listed in 2017.
• Cisplatin, also involved in two ongoing trials and cited in ten all-time medulloblastoma studies dating back to 2001. These treatments show great promise as researchers strive to find effective solutions for individuals battling this challenging form of cancer.

What are the most recent clinical trials for medulloblastoma?

Recent clinical trials offer hope for patients with medulloblastoma, a type of brain tumor. These studies are focused on improving treatment outcomes and exploring new therapeutic approaches. One trial, known as Arm A, is investigating the efficacy of a new treatment in relapsed/refractory CNS tumors including medulloblastoma. Another study, Phase I-Part B, aims to assess the safety and effectiveness of a potential therapy specifically for recurrent or refractory high-grade gliomas (HGG), which includes medulloblastoma. Additionally, cisplatin has been investigated in a Phase 2 trial to determine its impact on treating this aggressive tumor type. Furthermore, ongoing research also involves evaluating the use of chemoradiotherapy followed by maintenance therapy in a large-scale Phase 3 trial for medulloblastoma patients. Lastly, LUTATHERA®, an investigational drug utilizing lutetium Lu 177 dotatate is being studied across both Phase 1 and Phase 2 trials to explore its potential benefits for those affected by medulloblastoma.

What medulloblastoma clinical trials were recently completed?

Recent clinical trials have made significant strides in advancing the treatment of medulloblastoma, a type of brain cancer that primarily affects children. In May 2020, Emory University successfully completed a trial investigating the potential of WP1066 therapy for this aggressive disease. Furthermore, Sabine Mueller, MD, PhD led a groundbreaking study on Modified Measles Virus Lumbar Puncture back in February 2017. These important achievements reflect the dedication and determination of researchers to improve outcomes for patients fighting medulloblastoma.